Hydrogel could be potential treatment for metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 38% of the global population, with prevalence continuing to rise in parallel with the global burden of metabolic syndrome. Although several pharmacological agents are currently under clinical investigation, approved therapeutic options remain limited in both efficacy and scope.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Protein DUSP4 prevents immune cell exhaustion in colorectal cancer
United Kingdom
-
Collapsible bicycle helmets provide less protection on average than conventional helmets, new study finds
United Kingdom
-
Alternative pathways for blood vessel growth could become targets against drug-resistant tumors
United Kingdom
-
Mother-infant bonding linked to brain connectivity before birth
United Kingdom
-
Uncovering rules for aggressive brain tumors could lead to better treatments
United Kingdom
-
Mice that watch fights come away battle-ready
United Kingdom
-
Emergency surgery verification linked to lower death rates, shorter hospital stays
United Kingdom
-
Pulse oximetry–based scoring may miss sleep apnea events in Black patients
United Kingdom